FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366998625> ?p ?o ?g. }

• W4366998625 abstract "Ethiopia rolled out primaquine nationwide in 2018 for radical cure along with chloroquine for the treatment of uncomplicated Plasmodium vivax malaria in its bid for malaria elimination by 2030. The emergence of anti-malarial drug resistance would challenge the elimination goal. There is limited evidence on the emergence of chloroquine drug resistance. The clinical and parasitological outcomes of treatment of P. vivax with chloroquine plus radical cure using low dose 14 days primaquine were assessed in an endemic area of Ethiopia.A semi-directly observed 42-days follow up in-vivo therapeutic efficacy study was conducted from October 2019 to February 2020. Plasmodium vivax mono-species infected patients (n = 102) treated with a 14 days low dose (0.25 mg/kg body weight per day) primaquine plus chloroquine (a total dose of 25 mg base/kg for 3 days) were followed for 42 days to examine clinical and parasitological outcomes. Samples collected at recruitment and days of recurrence were examined by 18 S based nested polymerase chain reaction (nPCR) and Pvmsp3α nPCR-restriction fragment length polymorphism. Asexual parasitaemia and the presence of gametocytes were assessed on the scheduled days using microscopy. Clinical symptoms, haemoglobin levels, and Hillmen urine test were also assessed.Of the 102 patients followed in this study, no early clinical and parasitological failure was observed. All patients had adequate clinical and parasitological responses within the 28 days of follow up. Late clinical (n = 3) and parasitological (n = 6) failures were observed only after day 28. The cumulative incidence of failure was 10.9% (95% confidence interval, 5.8-19.9%) on day 42. Among the paired recurrent samples, identical clones were detected only in two samples on day 0 and day of recurrences (day 30 and 42) using Pvmsp3α genotyping. No adverse effect was detected related to the low dose 14 days primaquine administrations.Co-administration of CQ with PQ in the study area is well tolerated and there was no recurrence of P. vivax before 28 days of follow up. Interpretation of CQ plus PQ efficacy should be done with caution especially when the recurrent parasitaemia occurs after day 28. Therapeutic efficacy studies with appropriate design might be informative to rule out chloroquine or primaquine drug resistance and/or metabolism in the study area." @default.
• W4366998625 created "2023-04-27" @default.
• W4366998625 creator A5002233672 @default.
• W4366998625 creator A5030771026 @default.
• W4366998625 creator A5033074405 @default.
• W4366998625 creator A5034370177 @default.
• W4366998625 creator A5058378179 @default.
• W4366998625 creator A5060240343 @default.
• W4366998625 creator A5077380103 @default.
• W4366998625 creator A5077695054 @default.
• W4366998625 creator A5081998578 @default.
• W4366998625 date "2023-04-25" @default.
• W4366998625 modified "2023-10-14" @default.
• W4366998625 title "Treatment of uncomplicated Plasmodium vivax with chloroquine plus radical cure with primaquine without G6PDd testing is safe in Arba Minch, Ethiopia: assessment of clinical and parasitological response" @default.
• W4366998625 cites W109295324 @default.
• W4366998625 cites W1258628889 @default.
• W4366998625 cites W1785362826 @default.
• W4366998625 cites W1862670474 @default.
• W4366998625 cites W1900637665 @default.
• W4366998625 cites W1915861691 @default.
• W4366998625 cites W1969834934 @default.
• W4366998625 cites W1973364973 @default.
• W4366998625 cites W1974282434 @default.
• W4366998625 cites W1975267889 @default.
• W4366998625 cites W1996249048 @default.
• W4366998625 cites W2003819157 @default.
• W4366998625 cites W2020070256 @default.
• W4366998625 cites W2020736170 @default.
• W4366998625 cites W2022706035 @default.
• W4366998625 cites W2024475946 @default.
• W4366998625 cites W2032718210 @default.
• W4366998625 cites W2043762150 @default.
• W4366998625 cites W2051080253 @default.
• W4366998625 cites W2069419524 @default.
• W4366998625 cites W2080956225 @default.
• W4366998625 cites W2100476032 @default.
• W4366998625 cites W2101050651 @default.
• W4366998625 cites W2103493790 @default.
• W4366998625 cites W2107071499 @default.
• W4366998625 cites W2124740902 @default.
• W4366998625 cites W2125089473 @default.
• W4366998625 cites W2125984729 @default.
• W4366998625 cites W2131586368 @default.
• W4366998625 cites W2132107151 @default.
• W4366998625 cites W2132222410 @default.
• W4366998625 cites W2133150051 @default.
• W4366998625 cites W2137930030 @default.
• W4366998625 cites W2144016867 @default.
• W4366998625 cites W2146772833 @default.
• W4366998625 cites W2148406958 @default.
• W4366998625 cites W2158149195 @default.
• W4366998625 cites W2168670624 @default.
• W4366998625 cites W2169355407 @default.
• W4366998625 cites W2169511625 @default.
• W4366998625 cites W2179502240 @default.
• W4366998625 cites W2184357998 @default.
• W4366998625 cites W2205343376 @default.
• W4366998625 cites W2307122094 @default.
• W4366998625 cites W2322496896 @default.
• W4366998625 cites W2409051914 @default.
• W4366998625 cites W2462041221 @default.
• W4366998625 cites W2509785532 @default.
• W4366998625 cites W2615580270 @default.
• W4366998625 cites W2884033046 @default.
• W4366998625 cites W2898115386 @default.
• W4366998625 cites W2925512365 @default.
• W4366998625 cites W3125230024 @default.
• W4366998625 cites W4302373977 @default.
• W4366998625 cites W87464560 @default.
• W4366998625 doi "https://doi.org/10.1186/s12936-023-04562-x" @default.
• W4366998625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37098510" @default.
• W4366998625 hasPublicationYear "2023" @default.
• W4366998625 type Work @default.
• W4366998625 citedByCount "0" @default.
• W4366998625 crossrefType "journal-article" @default.
• W4366998625 hasAuthorship W4366998625A5002233672 @default.
• W4366998625 hasAuthorship W4366998625A5030771026 @default.
• W4366998625 hasAuthorship W4366998625A5033074405 @default.
• W4366998625 hasAuthorship W4366998625A5034370177 @default.
• W4366998625 hasAuthorship W4366998625A5058378179 @default.
• W4366998625 hasAuthorship W4366998625A5060240343 @default.
• W4366998625 hasAuthorship W4366998625A5077380103 @default.
• W4366998625 hasAuthorship W4366998625A5077695054 @default.
• W4366998625 hasAuthorship W4366998625A5081998578 @default.
• W4366998625 hasBestOaLocation W43669986251 @default.
• W4366998625 hasConcept C126322002 @default.
• W4366998625 hasConcept C142724271 @default.
• W4366998625 hasConcept C185032368 @default.
• W4366998625 hasConcept C190612196 @default.
• W4366998625 hasConcept C203014093 @default.
• W4366998625 hasConcept C2776793103 @default.
• W4366998625 hasConcept C2777425658 @default.
• W4366998625 hasConcept C2778048844 @default.
• W4366998625 hasConcept C2778371730 @default.
• W4366998625 hasConcept C2779997623 @default.
• W4366998625 hasConcept C71924100 @default.
• W4366998625 hasConcept C90924648 @default.
• W4366998625 hasConcept C99389464 @default.
• W4366998625 hasConceptScore W4366998625C126322002 @default.
• W4366998625 hasConceptScore W4366998625C142724271 @default.

• next